RXRX ▼ -5.0% - Recursion Pharmaceuticals, Inc.
$RXRX reported Q3 2026 EPS of -$0.22, beating the -$0.23 estimate by 4.3%. Revenue of $18.6M beat the $14.0M estimate by 32.2%.
02-NOV-2026 04:46 PM ET
Share this post
More filings for $RXRX
RXRX ▼ -5.5% - Recursion Pharmaceuticals, Inc.Nov 2, 2026RXRX ▼ -5.7% - Recursion Pharmaceuticals, Inc.Nov 2, 2026RXRX ▼ -5.5% - Recursion Pharmaceuticals, Inc.Nov 2, 2026RXRX ▲ +3.0% - Recursion Pharmaceuticals, Inc.Oct 26, 2026RXRX ▲ +0.3% - Recursion Pharmaceuticals, Inc.Oct 15, 2026RXRX ▼ -4.0% - Recursion Pharmaceuticals, Inc.Oct 15, 2026
View full $RXRX filing history →💬 Comments
Loading comments…
Leave a comment